Review Article: The Pharmacokinetics and Pharmacodynamics of Drugs Used in Inflammatory Bowel Disease Treatment

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2015 May 27

PMID 26008212

Citations 10

Authors

E G Quetglas

A Armuzzi

S Wigge

G Fiorino

L Barnscheid

M Froelich

Silvio Danese

Affiliations

Soon will be listed here.

Abstract

Background: The following review is a compilation of the recent advances and knowledge on the behaviour of the most frequently used compounds to treat inflammatory bowel disease in an organism.

Results: It considers clinical aspects of each entity and the pharmacokinetic/pharmacodynamic relationship supported by the use of plasma monitoring, tissue concentrations, and certain aspects derived from pharmacogenetics.

Citing Articles

Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis.

Vafaei S, Abdolghaffari A, Mahjub R, Eslami S, Esmaeili M, Abdollahi M Biomed Res Int. 2022; 2022:7776092.

PMID: 36203483 PMC: 9532096. DOI: 10.1155/2022/7776092.

Pep27 Mutant Immunization Inhibits Caspase-14 Expression to Alleviate Inflammatory Bowel Disease via Treg Upregulation.

Iqbal H, Kim G, Kim J, Ghosh P, Shah M, Lee W Microorganisms. 2022; 10(9).

PMID: 36144473 PMC: 9502188. DOI: 10.3390/microorganisms10091871.

Development of An HPLC Method for the Determination of Mesalazine in Human Plasma by Fluorimetric Derivatization and Application to A Prototype Pharmacokinetic Study.

Ceylan B, Kepekci Tekkeli E, Onal C J Fluoresc. 2021; 32(1):319-325.

PMID: 34797459 DOI: 10.1007/s10895-021-02848-4.

Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond.

Di Paolo A, Luci G Front Pharmacol. 2021; 11:610806.

PMID: 33628180 PMC: 7898166. DOI: 10.3389/fphar.2020.610806.

Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.

Al-Ani A, Prentice R, Rentsch C, Johnson D, Ardalan Z, Heerasing N Aliment Pharmacol Ther. 2020; 52(1):54-72.

PMID: 32348598 PMC: 7267115. DOI: 10.1111/apt.15779.

References

Hawthorne A, Logan R, Hawkey C, Foster P, Axon A, Swarbrick E . Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305(6844):20-2. PMC: 1882467. DOI: 10.1136/bmj.305.6844.20. View

Webster A, Woodroffe R, Taylor R, Chapman J, Craig J . Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2005; (4):CD003961. DOI: 10.1002/14651858.CD003961.pub2. View

Lilleyman J, Lennard L . Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet. 1994; 343(8907):1188-90. DOI: 10.1016/s0140-6736(94)92400-7. View

Fasanmade A, Adedokun O, Olson A, Strauss R, Davis H . Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010; 48(5):297-308. DOI: 10.5414/cpp48297. View

Klotz U . Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985; 10(4):285-302. DOI: 10.2165/00003088-198510040-00001. View

Sandborn W, Colombel J, Panes J, Castillo M, Robinson A, Zhou Q . Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials. J Crohns Colitis. 2013; 7(12):958-67. DOI: 10.1016/j.crohns.2013.02.016. View

Ryrfeldt A, Edsbacker S, Pauwels R . Kinetics of the epimeric glucocorticoid budesonide. Clin Pharmacol Ther. 1984; 35(4):525-30. DOI: 10.1038/clpt.1984.71. View

Press O, Hansen J, Farr A, Martin P . Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes. Cancer Res. 1988; 48(8):2249-57. View

Zintzaras E, Dahabreh I, Giannouli S, Voulgarelis M, Moutsopoulos H . Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther. 2008; 30(11):1939-55. DOI: 10.1016/j.clinthera.2008.11.007. View

10.

Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y . Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol. 2002; 29(12):2492-9. View

11.

Lindqvist M, Haglund S, Almer S, Peterson C, Taipalensu J, Hertervig E . Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics. 2004; 14(4):261-5. DOI: 10.1097/00008571-200404000-00006. View

12.

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

13.

Weinshilboum R, Raymond F, Pazmino P . Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978; 85(3):323-33. DOI: 10.1016/0009-8981(78)90311-x. View

14.

Herrlinger K, Cummings J, Barnardo M, Schwab M, Ahmad T, Jewell D . The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics. 2005; 15(10):705-11. DOI: 10.1097/01.fpc.0000172242.19675.33. View

15.

Ptachcinski R, Venkataramanan R, Rosenthal J, Burckart G, Taylor R, Hakala T . Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther. 1985; 38(3):296-300. DOI: 10.1038/clpt.1985.174. View

16.

Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M, Derendorf H . Pharmacokinetics and rectal bioavailability of hydrocortisone acetate. J Pharm Sci. 1991; 80(9):835-6. DOI: 10.1002/jps.2600800906. View

17.

Sprakes M, Ford A, Warren L, Greer D, Hamlin J . Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012; 6(2):143-53. DOI: 10.1016/j.crohns.2011.07.011. View

18.

Comber P, Gomez F, Rossman M, Schreiber A . Receptors for the Fc portion of immunoglobulin G (Fc gamma R) on human monocytes and macrophages. Prog Clin Biol Res. 1989; 297:273-85. View

19.

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

20.

Rutgeerts P, Van Assche G, Vermeire S . Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006; 23(4):451-63. DOI: 10.1111/j.1365-2036.2006.02786.x. View